Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.
Bradley J. Monk, MD, FACS, FACOG, University of Arizona
Advertisement
Articles by Bradley J. Monk, MD, FACS, FACOG, University of Arizona
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5